Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
1.280
+0.070 (5.79%)
At close: Aug 13, 2025, 4:00 PM
1.300
+0.020 (1.56%)
After-hours: Aug 13, 2025, 6:50 PM EDT
PACB Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for PACB stock ranges from a low of $1.50 to a high of $3.00. The average analyst price target of $1.91 forecasts a 49.22% increase in the stock price over the next year.
Price Target: $1.91 (+49.22%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PACB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 1 | 1 | 1 |
| Buy | 4 | 4 | 3 | 3 | 3 | 2 |
| Hold | 6 | 6 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 9 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $1.25 → $1.5 | Hold | Maintains | $1.25 → $1.5 | +17.19% | Aug 11, 2025 |
| Barclays | Barclays | Hold Maintains $2 → $1.5 | Hold | Maintains | $2 → $1.5 | +17.19% | Jun 25, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $2 → $1.25 | Hold | Maintains | $2 → $1.25 | -2.34% | May 15, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $1.8 | Buy | Reiterates | $1.8 | +40.63% | May 15, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $3 | Strong Buy | Maintains | $3 | +134.38% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
159.19M
from 154.01M
Increased by 3.36%
Revenue Next Year
188.16M
from 159.19M
Increased by 18.20%
EPS This Year
-1.49
from -1.13
EPS Next Year
-0.55
from -1.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 168.2M | 210.8M | 268.7M | ||
| Avg | 159.2M | 188.2M | 231.0M | ||
| Low | 148.0M | 161.2M | 176.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.2% | 32.4% | 42.8% | ||
| Avg | 3.4% | 18.2% | 22.8% | ||
| Low | -3.9% | 1.3% | -6.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.68 | -0.40 | -0.24 | ||
| Avg | -1.49 | -0.55 | -0.41 | ||
| Low | -1.96 | -0.70 | -0.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.